Bexmarilimab plus doxorubicin for advanced soft-tissue sarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called bexmarilimab combined with doxorubicin for people with soft-tissue sarcoma that has spread to other parts of the body. The goal is to see if the combination is safe and works better than doxorubicin alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have a type of soft-tissue sarcoma that has spread (metastatic).
- You haven't had doxorubicin or immunotherapy before.
- Your tumor can be measured on scans.
- Your blood counts, liver, and kidney function are within certain limits.
- You agree to use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two chemotherapy drugs—utidelone and doxorubicin—for people with advanced soft tissue sarcoma. The goal is to see if this combination can help shrink or slow the cancer.
This trial tests a new drug, HS-20093, combined with other treatments for people with advanced bone or soft tissue sarcoma. The goal is to see if these combinations can shrink tumors or slow their growth.
This trial is testing a new combination of four treatments (an experimental drug, two chemo-like drugs, and radiation) for advanced soft tissue sarcoma that hasn't responded to earlier treatments. The goal is to see if this combination can help shrink or slow the cancer.
This trial tests a combination of radiation therapy and two drugs (anlotinib and penpulimab) given before surgery for soft tissue sarcoma. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial is testing a new treatment for advanced dedifferentiated liposarcoma that has not been treated yet. The goal is to see if the treatment can help shrink or slow the cancer.
This study tests whether adding an investigational drug called BOLD-100 to a standard chemotherapy (doxorubicin) helps people with certain types of advanced soft tissue sarcoma. It might slow tumor growth or shrink tumors.
Hear when a new Soft Tissue Sarcoma (STS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.